- Question from DianneLi: What phase was the PARP inhibitor study in triple-negative women? How long will it be until PARP inhibitors are available to us?
- Answers - Kathy D. Miller, M.D. That's the question we would all like to know! The PARP inhibitor study that was reported earlier this year at ASCO was a randomized Phase II study that enrolled about 120 women. The FDA has required that those results be verified in a larger randomized Phase III trial. That Phase III trial is ongoing and will likely finish enrolling patients early next year, but it's difficult to predict how quickly we will have the results and perhaps more importantly how quickly the FDA will act once the results are available.
On Tuesday, December 15, 2009, our Ask-the-Expert Online Conference was called Updates from the 2009 San Antonio Breast Cancer Symposium. Kathy Miller, M.D. and Kristin Brill, M.D., F.A.C.S. answered your questions about the latest updates on breast cancer risk, screening techniques, treatment options, and more.
The materials presented in these conferences do not necessarily reflect the views of Breastcancer.org. A qualified healthcare professional should be consulted before using any therapeutic product or regimen discussed. All readers should verify all information and data before employing any therapies described here.
A production of LiveWorld, Inc.
Copyright 2010. All rights reserved.